Abstract | The role of p63 in cancer has been an area of intense debate and controversy. Is TP63 (which encodes p63) a tumour suppressor gene or an oncogene? This debate is partly due to the complexity of the gene. There are several p63 isoforms -some with tumour suppressive functions and others with oncogenic functions. In this Opinion article, we focus on the recent advances in understanding p63 biology and its roles in cancer. In this regard, we discuss the role of p63 in multiple stem cell compartments, ageing, in the response to DNA damage and in DNA repair. Finally, we highlight the importance of understanding the interactions between all three p53 family members and the potential impact of this knowledge on cancer therapy and regenerative medicine.
; however, the tumour suppressive roles of p63 and p73, which are p53 family members, have been less clear. More than 10 years after the discovery of TP63 and TP73 , specific isoforms of p63 and p73 have now been widely accepted as having tumour sup pressive functions [7] [8] [9] [10] [11] . The road leading to this discovery has not been an easy one. Studies of the expression patterns of p63 in human cancer in the late 1990s and early 2000s were confusing and led to contradictory results (Supplementary information S1 (table)). These results left researchers perplexed as to whether p63 suppresses or promotes tumori genesis. This confusion was mostly due to the complex structure of the TP63 gene and also due to antibodies that did not distinguish between the different isoforms of p63 (FIG. 1) . p63 is encoded by the ancestral gene of the p53 family 3, 12 and is of particular interest owing to its essential role and high expression in epithelial tissues 13, 14 . TP63 encodes multiple isoforms that can be placed in two catego ries: isoforms with an acidic transactivation domain, which are known as the TA isoforms; and isoforms that lack this domain, which are known as the ΔN isoforms (FIG. 1) . Data from in vitro experiments have provided evidence that the TA isoforms of TP63 are tumour suppressor genes and that the ΔN isoforms of TP63 are oncogenes, which antagonize p53, TAp63 and TAp73 by inhibiting their ability to transactivate downstream target genes 8, 9, 12, 15 . Further in vivo work has recently demonstrated that the TAp63 and TAp73 isoforms are tumour suppressors in mice [8] [9] [10] . Both TP63 and TP73 also contain several carboxyterminal spliced isoforms (FIG. 1) . These isoforms transactivate target genes to varying degrees, which then induce cel lular functions, such as apoptosis, cell cycle arrest and senescence 8, 12, 15, 16 . The TAp63γ and TAp73β isoforms, which most closely resemble p53, are the most transcriptionally active isoforms to induce apoptosis 12, 15, 17 . The activity of each isoform in other biological processes is still not completely understood but is an area of intense investigation.
Much of the research carried out on p63 has focused on its role in the morphogenesis of epidermal tissues. Mice lacking all iso forms of Trp63 (which encodes p63 in mice) do not have complete stratified epithelia 13, 14 , and the mechanisms used by p63 to regulate epithelialization have important implications for cancer and metastasis. In this Opinion article, we summarize the current literature on the p53 family, with an emphasis on p63 and its roles in cancer, metastasis, DNA damage, ageing and stem cell biology. We also discuss the intricate interplay of p63 with the other p53 family members.
Functions of p63: in vitro studies
Transcriptional activity. p53 induces multiple cellular processes, including apoptosis and cell cycle arrest in response to DNA damage, by transactivating a large network of genes, including BCL2associated X protein (BAX), BCL2 binding component 3 (BBC3; also known as PUMA), PMAIP1 (also known as NOXA), PERP and cyclindependent kinase inhibitor 1A (CDKN1A; which encodes p21) 12, 15 . These biological activities are impor tant for the function of p53 in the DNA dam age response and for its function as a tumour suppressor. New mouse models with novel p53 mutations have revealed the crucial activ ities and transcriptional targets of p53 that are necessary for its function in tumour suppres sion 18, 19 . Mice with mutations in one of the transactivation domains of p53 (REFS 25, 26) retained the ability to transactivate genes that are involved in senescence and were still able to suppress tumorigenesis. This form of p53 is unable to induce G1 phase arrest and apoptosis, indicating that these functions of p53 are dispensable for tumour suppression 18 . More recently, the role of p53 in metabolism was revealed to be key to its tumour suppres sive function. This was demonstrated using a mouse model harbouring three mutations at acetylation sites of p53 (p53 3KR) 19 . This mutant form of p53 fails to induce target genes that are involved in cell cycle arrest, apoptosis and senescence, but mice express ing this p53 mutant do not succumb to the rapid development of thymic lymphomas that is seen in p53deficient mice 20, 21 . This form of p53 retains its tumour suppressive function through its ability to transactivate glutami nase 2 (GLS2), which encodes an enzyme that regulates glutamine use and promotes mito chondrial respiration and ATP production.
TAp63 shares structural and sequence homology with p53 (FIG. 1) and TAp73. Consequently, TAp63, p53 and TAp73 bind as tetramers to similar consensus sequences to transactivate downstream target genes 12, 17, 22, 23 . Each can form homotetramers, and TAp63 and TAp73 can also form heterotetramers 22 . The TA isoforms of p63 are potent transac tivators of the wellknown p53 target genes CDKN1A, BAX and MDM2 (FIG. 2) , whereas the ΔNp63 isoforms do not transactivate these targets to high levels 12 . The ΔNp63 isoforms also have the ability to transactivate downstream target genes such as CDKN1A, resulting in the inhibition of cellular prolif eration 24 . This transcriptional activation is possible through a prolinerich domain that is located at the amino terminus of ΔNp63 isoforms 24 , and the mechanisms of p53 family target selectivity and transcriptional activity is an area of much investigation in the field.
Differences between p53 and p63 bind ing to target sequences have been found, and these are due to differences in the DNA binding motif and in the threedimensional (3D) structures of p53 and p63. The p53 con sensus binding site contains two repeats of ten base pairs known as halfsites (RRRC(A/T) (A/T)GYYY) that are separated by a spacer sequence of 0-13 base pairs 25 . Tetramerization of p53 is dependent on the oligomerization domain that is present in the C terminus. p53 tetramers are composed of symmetric dimers of dimers that each binds a halfsite. Similarly, both p63 and p73 form homo tetramers, and in some cases hetero tetramers, with each other 22, 23 . The optimal p63 DNA binding consensus motif was found to dif fer slightly from that of p53: it is enriched for CATG in the cores of both half sites (RRRCATGYYY) 17 . These data suggest that the p63 isoforms may have distinct transcrip tional targets from p53 (REFS 9, 16, 17, 26, 27) . Indeed, several unique targets of p63 have been identified using Trp63 −/− mouse embry onic fibroblasts (MEFs) or immortalized human keratinocytes (HaCaT cells) and highthroughput technologies, such as cDNA and microRNA (miRNA) microarrays and chromatin immunoprecipitation-microarray (ChIP-chip) 17, 23, 27, 28 . TAp63 can transactivate genes that are involved in miRNA biogenesis (such as DICER1) 9 , in the cell cycle (Cdkn1c; which encodes p57) 16 and in epidermal stratification (transcription factor AP2γ (TFAP2C)) 29 . ΔNp63 isoforms transactivate genes that are involved in epidermal morpho genesis 17, 28, 30 . Interestingly, the ΔNp63 and ΔNp73 isoforms were also found to be potent transcriptional activators of genes that are involved in DNA repair, including Brca2, Rad51 and Mre11a
27
. Moreover, ΔNp63 coop erates with ΔNp73 for full transactivation of these genes 27 . These data indicate that the ΔN isoforms of both p63 and p73 may also have tumour suppressive functions through their ability to transactivate genes that are crucial for DNA repair. Although data from in vitro analyses of tissue culture cells support this conclusion, further in vivo data using mouse models are required to fully understand the potential tumour suppressive activities of ΔNp63. Such in vivo analyses have been car ried out to understand the functions of the TAp63 isoform using mouse models, but the potential tumour phenotypes of ΔNp63-and ΔNp73deficient mice have not been fully studied.
In addition to the transactivation activity of the ΔNp63 isoforms, they can also antago nize p53 and the TA isoforms of p63 and p73. This is because interactions between iso forms of p63, p73 and p53 result in complex biological responses. ΔNp63 can inhibit p53, TAp63 and TAp73 transcriptional activity in a dosedependent manner 12 by competing for DNA consensus sites 23 . The inhibition of p53, TAp63 and TAp73 suggests that the ΔNp63 and ΔNp73 isoforms have oncogenic poten tial. Indeed, ΔNp63 and ΔNp73 can inhibit apoptosis in cells in vitro 12, 31, 32 . The TAp63 and TAp73 isoforms can also be inhibited through interactions with cancerassociated p53 mutants 33, 34 . These interactions result in the inability of the TA isoforms to induce tumour suppressive cellular processes, such as apoptosis, through the formation of pro tein complexes that are unable to bind to DNA at the promoters of target genes 23, 33, 34 . This complex interplay between the p53 fam ily members indicates the need for a clear mechanistic understanding of the activities of this family in DNA damage responses.
The 3D structure formed by p53 and p63 monomers affects DNA binding affinity and downstream transcriptional target selectivity. The p63 monomer structure is similar to that of p53 with the exception of the LB2 and L1 loops, which are necessary for dimer-dimer interface interactions 35 . Complex regula tion by the conversion of TAp63α dimers to tetramers was recently found to be crucial for the response to DNA damage in mouse oocytes 36 . In addition to DNA binding sequences and 3D structure, cofactors, such as p300, which bind to p63, p53 and p73, determine the specificity and the selectivity of downstream transcriptional targets 37, 38 . Post-translational modifications. Post translational modifications of p63, p73 and p53 have important roles in the induction and the stabilization of the proteins. In response to genotoxic stress, both p53 and TAp63 rapidly accumulate 1, 15 . The accumula tion of p53 is due to the inability of MDM2 to bind and degrade phosphorylated p53 (REF. 39 ). p63 and p73 can also interact with MDM2 and MDM4 (also known as MDMX). However, MDM2 and MDM4 do not target either p63 or p73 for degradation 40, 41 . The interaction of TAp63 with MDM2 results in the translocation of TAp63 to the cytoplasm, Figure 1 | p53, p63 and p73 sequence and structural similarity. TP63 and TP73 are composed of multiple isoforms that can be placed in two categories: the TA isoforms, which contain an acidic transactivation (TA) domain that is encoded by the first three exons; and the ΔN isoforms, which lack this amino-terminal domain. Shown for both TP63 and TP73 are the α, β and γ-isoforms, which are determined by alternative splicing of the carboxyl terminus. TP53, TP63 and TP73 share sequence nucleotide similarity in three regions: the TA domain, the DNA binding domain (DBD) and the oligomerization domain (OD). Numbers shown represent shared percentage identity between TP53, TP63 and TP73. Only the p63α and p73α isoforms contain a sterile alpha motif (SAM) domain in both the TA and the ΔN isoforms. Nature Reviews | Cancer
Cell cycle arrest Apoptosis Metabolism which in turn inhibits apoptosis 42 . Biological roles for TAp63 in the cytoplasm have not yet been identified. Like p53, TAp63 and TAp73 are also phosphorylated in response to DNA damage [43] [44] [45] [46] [47] . For example, TAp63γ is phos phorylated by inhibitor of nuclear factorκB kinaseβ (IKKβ) in response to ionizing radiation, resulting in the stabilization of TAp63γ 45 . TAp73 is phosphorylated by the tyrosine kinase ABL (also known as ABL1) in response to genotoxic stress that is induced by cisplatin 43, 44, 46, 47 . The full complement of posttranslational modifications for p63, p73 and their various isoforms is still an area that has not been extensively investigated.
Although MDM2 and MDM4 are not crucial for p63 turnover, other E3 ubiquitin ligases have been shown to target p63 for ubiquitylation and subsequent degradation. Both TAp63α and ΔNp63α are targeted for ubiquitylation by the E3 ubiquitin ligase ITCH 48 . Isoforms of p73 are regulated in a similar manner 49 . The regulation of ΔNp63 seems to be coordinated in a more sophis ticated manner by two scaffold proteins, syntaxinbinding protein 4 (STXBP4) and receptor of activated kinase C1 (RACK1; also known as GNB2L1), which bind to ΔNp63 (REF. 50 ). On genotoxic stress, STXBP4 is downregulated and this results in ΔNp63 destabilization through RACK1, a scaf fold protein that adopts a sevenbladed βpropeller structure to facilitate binding to E3 ubiquitin ligases. This binding in turn targets ΔNp63 for proteasomal degradation 50 .
Tissue and cellular specificity. The complex ity of p53 family member interactions in response to DNA damage and apoptosis was revealed using mice deficient for Trp53, Trp63 and Trp73 (REF. 15) (FIG. 2) . p53 was found to require the expression of p63 and p73 to induce target genes that are involved in apop tosis in the developing brain and in MEFs in response to DNA damage 15 . However, the requirement of the whole family for the induction of apoptosis seems to be tissue dependent. Thymocytes that were deficient for Trp63 and Trp73 were as sensitive to genotoxic stress as wildtype thymocytes and they underwent apoptosis, indicating that p53 is functional in this context 51 . The differing results of the two studies are probably due to differences in tissue expression between the p53 and the p63 isoforms. Although p53 is ubiquitously expressed, p63 is mostly expressed in epithelial tissues 13, 14 , neurons 52 and the germ line 53, 54 . Another group of researchers found that p63 is not detectable in neurons and that p73 is essential for the development of the central nervous system (CNS) 55 . Although this result indicates that p63 is not necessary for CNS development, it does not exclude the possibility that p63 may have a role in the response to stress in this tissue. In addition, TAp63 isoforms are expressed in response to DNA damage or other stresses in the epithelium, neurons and the germ line 15, 53, 54, 56 , whereas ΔNp63 iso forms are constitutively expressed in the basal compartment of the epidermis and in other epithelial tissues and are not induced by DNA damage 13, 14, 30 . Conversely, ΔNp63 is degraded in response to genotoxic stress 50 . These spatial and temporal differences in the expression of the p53 family members and the p63 isoforms lead to differences in the transcriptional programme that is activated by each.
Examples of target gene specificity and selectivity by distinct p63 isoforms have been best demonstrated in the skin and germ line 16, 30, 54 . In the skin, TAp63 is expressed in stem cells known as skinderived pre cursors (SKPs), which are derived from SOX2positive hair follicle dermal cells 16 . Conversely, ΔNp63 is expressed in tran siently amplifying cells in the basal layer of the epidermis 30 . This expression pattern results in the transactivation of specific tar get genes, Cdkn1c for TAp63 in SKPs 16 and keratin 14 (Krt14) by ΔNp63 in basal cells of the epidermis 30 . An additional example of tissue specificity is in the female germ line: p63 has a crucial role in maintaining the genome of mouse oocytes, and these functions are independent of p53 (REF. 54 ). In this regard, TAp63 induces apoptosis through transcriptional activation of Bbc3 and Pmaip1 in a p53independent manner 54 . More recently, a unique isoform of TAp63 that is present only in human and ape testes was found to protect the male germ line by inducing apoptosis 53 . Thus, TAp63 has now been dubbed the 'guardian' of the germ line.
Similarly, p73 is expressed in specific tissues, including in neurons, lung, kidney and pancreas 7, 10, 57 . Studies of mice express ing mutant p73 have revealed that p73 has important roles in the development of the CNS 58 , neurodegeneration 59 and in cancer 7, 11 . More specifically, TAp73 has been found to be crucial for the maintenance of neural stem cells 57, [60] [61] [62] [63] . Additionally, mice lacking TAp73 are prone to the development of lung adenocarcinoma 10 . Collectively, these studies highlight the importance of understanding the p53 family as a whole in response to vari ous DNAdamaging agents in different tissue and cellular contexts. a | Subsequent to DNA damage, which can be induced through treatment with ionizing radiation, doxorubicin or cisplatin, p53, TAp63 and TAp73 activate downstream transcriptional targets to induce multiple cell fates. p53, TAp63 and TAp73 can transcriptionally activate cyclin-dependent kinase inhibitor 1A (CDKN1A; which encodes p21) individually to induce cell cycle arrest. b | Subsequent to DNA damage, TAp63 and TAp73 are required in complex with p53 to transcriptionally activate genes that are involved in apoptosis, including BCL-2 binding component 3 (BBC3; also known as PUMA), BCL-2-associated X protein (BAX), PMAIP1 (also known as NOXA) and PERP. c | p53, TAp63 and TAp73 transactivate genes that are involved in metabolism. TAp63 transactivates sirtuin 1 (SIRT1), STK11 (also known as LKB1) and PRKAA2 (also known as AMPKΑ2) to regulate glucose and lipid metabolism. TAp73 transactivates cytochrome c oxidase subunit IV isoform 1 (COX4I1), which is a subunit of the mitochondrial multimeric enzyme that executes the last step in aerobic respiration. p53 transactivates C12ORF5 (also known as TIGAR) and glutaminase 2 (GLS2), which are crucial for its function as a tumour suppressor.
Functions of p63: in vivo mouse models
The in vitro experiments carried out in tissue culture cells have provided crucial infor mation about the function of the different isoforms of p63. The TAp63 isoforms have been shown to activate transcriptional target genes that induce apoptosis, which is consist ent with a role for these isoforms as tumour suppressors 12, 15 . By contrast, the roles of the ΔNp63 isoforms seem to be more complex. The ΔNp63 isoforms can inhibit p53, TAp63 and TAp73 function, which is consistent with a role for the ΔNp63 isoforms as onco genes 12 . The oncogenic potential of ΔNp63α was demonstrated in a cellular model in which this p63 isoform was shown to bypass HRASG12Vinduced senescence to promote the proliferation of a KRT15positive stem cell population in the skin 64 . The ΔNp63 isoforms can transactivate genes that are involved in DNA repair 27 , which is consistent with a role for these isoforms as tumour suppressors. Additionally, some human tumours have been reported to overexpress ΔNp63 isoforms (Supplementary information S1 (table)), consistent with oncogenic roles, and others have been shown to lose expression of ΔNp63 isoforms, further indicating that these iso forms may also function as tumour suppressor genes 65 . Recent mouse models that were engi neered to express p63 mutations have revealed important and unique p53independent func tions of p63 that are associated with cancer. TAp63 has crucial roles in maintaining stem cells in quiescence and in preventing pre mature ageing 16 , as well as in senescence 8, 9, 16 . These activities are crucial for TAp63 to func tion as a tumour suppressor. Mice engineered with knocked down 30 or total loss of expres sion 66 of ΔNp63 revealed that ΔNp63 is crucial for the terminal differentiation of cells in the epidermis. The cancerassociated phenotypes of these mouse models of ΔNp63 have not yet been reported. p63 in the suppression of tumorigenesis and metastasis. Mouse models with p63 muta tions have revealed that TAp63 is a suppressor of tumorigenesis and metastasis [7] [8] [9] . This was first demonstrated in doubleheterozygous ) are similarly transformed to MEFs that are defi cient for all three p53 family members. These MEFs were generated from Trp53deficient embryos, and small interfering RNA (siRNA) was used to knock down p63 and p73 expres sion 7, [67] [68] [69] . These data further suggest that the p53 family as a whole is involved in the sup pression of tumorigenesis. More recently, p53 and p63 were shown to extensively interact to suppress metastasis. Transforming growth factorβ (TGFβ)dependent migration, inva sion and metastasis of breast cancer cells were driven by mutant p53 through the inhibition of p63 (REF. 70) (FIG. 3) . Moreover, mutant p53 was found to drive invasion by promoting 
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integrin recycling through the inhibition of TAp63 (REF. 71) (FIG. 3) . This mechanistic insight into p53-TAp63 interplay in the sup pression of metastasis highlights the impor tance of understanding the mechanistic roles of TAp63 in the suppression of tumorigenesis and metastasis.
To further investigate the mechanisms of tumour suppression by TAp63, the creation of TAp63 −/− mice was essential. Indeed, TAp63 −/− mice developed metastatic mam mary and lung adenocarcinoma, and squa mous cell carcinoma, with metastases to the lung, liver and brain 9 . TAp63 was found to suppress metastasis through the transcrip tional activation of Dicer1 and the miRNA mir-130b 9 (FIG. 3) . Given the extensive network of genes regulated by miRNAs, the finding that TAp63 transcriptionally regulates Dicer1 and mir-130b has many important implica tions for the role of TAp63 isoforms in mul tiple biological processes. Understanding the miRNA network that is regulated by TAp63 isoforms in individual cancers could be important for designing targeted therapy for metastatic cancers. p63 in longevity. Ageing is a risk factor for the development of cancer. The incidence of cancer rises exponentially after the age of 50 years. Although ageing is known to accel erate the frequency of tumorigenesis, the cel lular activities that are associated with ageing, such as senescence, can also have a tumour suppressive role in certain tissues 9, 18, 72, 73 . This dichotomy of senescence and ageing in tumour suppression has also been dem onstrated using knockout mouse models of Trp63. Several of these mouse models have revealed that premature senescence or ageing leads to reduced tumour incidence (TABLE 1 72, 73 . Although this result is at odds with the previously reported Trp53
, which had an increase in tumour incidence and metastasis, more recently published data help to shed light on the differing phenotypes of these mouse models that harbour different alleles of Trp53 and Trp63. First, it has been reported that the (tm1Fmc) mice. Taken together, these data indicate that premature ageing that is induced by the total loss of TAp63 results in the suppression of metastatic osteosarcomas but also in the acceleration of aggressive and metastatic carcinomas. Therefore, ageing tissues seem to have differing sensitivities to tumour formation, and understanding the molecular mechanisms of tumour suppres sion by p63 and the other p53 family mem bers in different tissue contexts is crucial to treating cancer effectively.
Further studies are required to fully understand the complex function of TAp63 isoforms in tumour suppression in various tissue and cellular contexts. Additionally, the mammary adenocarcinoma phenotypes of the Trp53
(tm1Fmc) mice suggest that ΔNp63 isoforms may also have a tumour suppressive role, perhaps through the ability of ΔNp63 isoforms to transactivate genes in the DNA repair path way (Brca2, Mre11a and Rad51) 27 . Further experiments using ΔNp63deficient mice are needed to test this possibility. p63 in the maintenance of stem cells in epithelial tissues. The role of p63 in skin stem cells has been another controversial area. p63 is highly expressed in the basal layer of the epi thelium where stem cells and transient amplifying cells reside 13, 14, 56 . The analysis of multiple mouse models that lacked all iso forms of p63 led to the conclusion that p63 has crucial roles in epithelial morphogenesis and that it is necessary either for stem cell renewal 14, 56, 75 or for terminal differentiation 13, 30 . Some researchers have further demonstrated, using keratinocytes that were deficient for p63, that it is crucial for stem cell proliferation 75 , and others have argued that p63 is dispensa ble for this function but that it is crucial for terminal differentiation 30 . The most highly expressed isoform of p63 in the basal layer of epithelial tissues is ΔNp63α (FIG. 4) . Studies have shown that ΔNp63 transcriptionally activates genes that are required for terminal differentiation, such as KRT14, suppressor of fused homologue (SUFU), homeobox C4 (HOXC4) and myelin protein zero like 2 (MPZL2; also known as EVA1) 17, 28, 30 . Importantly, TAp63 and ΔNp63 also tran scriptionally activate PERP, which is crucial for the assembly of desmosomal adhesive com plexes and epidermal integrity 15, 76 . Recently, 
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Basement membrane the function of TAp63 in stem cells in the skin has been more carefully characterized. Using TAp63 −/− mice, TAp63 was found to maintain dermal stem cells in quiescence through the transcriptional activation of Cdkn1c (which encodes p57) 16 (FIG. 4) . SOX2positive hair follicle dermal stem cells (SKPs) deficient for TAp63 are hyperproliferative in vitro and in vivo and have high levels of genomic instability 16 . These data provide at least one mechanism by which TAp63 suppresses tumorigenesis: through the suppression of the aberrant proliferation of adult stem cells, such as SKPs. Another mechanism for tumour suppression by TAp63 is through its ability to induce senescence in response to oncogenic stress 8 . Indeed, TAp63 −/− mice are prone to developing metastatic cutaneous squamous cell carcinomas 9 , and these may arise from hyperproliferating SKPs, in which TAp63 has an essential role in maintaining quiescence.
Taken together, the roles of the p63 iso forms in epithelial stem cells have impor tant implications for cancers arising from epithelial tissues. Moreover, the roles of the p63 isoforms in cancer stem cells will probably be an area of further research.
Functions of p63 in human cancer
Multiple studies using samples from human patientderived tumours have been carried out to determine the status of p63 expres sion. The results from these studies are sum marized in Supplementary information S1 (table) . In many studies, researchers have used antibodies raised against the DNA binding domain of p63, and these antibodies do not distinguish between the TA and the ΔN isoforms. Consequently, early studies indicated that p63 is expressed in tumours (Supplementary information S1 (table)), which is consistent with an oncogenic role for p63. The examination of large sets of paraffinembedded patient samples indi cated that p63 is expressed in the nucleus of cells from many tumour types, including multiple types of head and neck cancers 9, [77] [78] [79] , diffuse large B cell lymphoma 80 and bladder carcinoma [81] [82] [83] [84] [85] [86] . Although p63 expression was typically located in the nucleus, some cases of prostate carcinoma expressed p63 in the cytoplasm 87 , suggesting that p63 may not be functional in these tumours or that p63 may have cytoplasmic roles, as has been reported for p53 (REF. 88) . Interestingly, in a study of 2,158 oestrogen receptor (ER)positive breast cancers, lowgrade tumours expressed p63, whereas highgrade tumours were devoid of p63 expression 89 , suggesting that p63 is involved in suppressing tumour progression in these tumours.
Studies using antibodies or PCR primers that distinguish between the TA and the ΔN isoforms of p63 in human patient tumour samples showed that the TA isoforms of p63 either are not expressed or are expressed at very low levels 9, 77 . Conversely, the ΔNp63 isoforms are expressed at high levels 78, 83, 90 . These expression patterns are consistent with TAp63 functioning as a tumour suppressor gene and ΔNp63 functioning as an oncogene. Importantly, there are several examples of tumours in which the loss of TAp63 expres sion has been found in invasive and meta static lesions, including bladder carcinoma, mammary and lung adenocarcinoma, and head and neck squamous cell carcinoma, which is consistent with its function as a metastasis suppressor (Supplementary infor mation S1 (table) ). Low expression of TAp63 frequently coincides with high expression of ΔNp63 in lesions that have progressed.
Although p53 is commonly mutated in human cancer, the mutation status of p63 has not been well studied. Some p63 muta tions, which are located in the DNA binding domain or in the transactivation domain and that inhibit the transactivation of p63 target genes, are associated with various syndromes, including ectrodactyly, ectodermal dyspla sia and cleft lip/palate syndrome (EEC), ankyloblepharonectodermal defectscleft lip/palate syndrome (AEC), limb mammary syndrome (LMS), acrodermatoungual lacrimaltooth (ADULT) syndrome and Rapp-Hodgkin syndrome (RHS). Interestingly, these patients do not seem to be prone to developing tumours 91 , suggesting that mutations of p63 are not driver mutations in cancer. However, some mutations of p63 have been identified in patient tumour samples in the DNA binding domain in exon 4 of TP63 (Supplementary information S1 (table)), which affect the transactivation of both the TA and the ΔN isoforms of p63 (REF. 92 ). With the advent of lowcost highthroughput sequenc ing, additional mutations and alterations in p63 are likely to be unveiled throughout the gene in a similar manner to TP53. Much like p53, there will probably be mutations that affect the ability of p63 isoforms to bind to DNA and there could also be others in regions that disrupt protein-protein interac tions that are crucial for the downstream transcriptional activation of target genes that function in cellular processes that suppress tumorigenesis. Furthermore, it will be impor tant to generate mutations in p63 in mice that will allow further dissection of the regions and activities of the p63 protein, which will allow us to determine the biological functions of p63 that are crucial for tumour suppression, as has been done for p53 (REFS 18, 19) .
Conclusions and future directions
It is clear from the multiple cellular processes regulated by members of the p53 family through the transcriptional regulation of downstream target genes that they are impor tant suppressors of tumorigenesis. The ability of the family members to induce apoptosis, cell cycle arrest, senescence and metabolic reg ulation in response to environmental stresses is key to the suppression of tumour forma tion. The complex interplay between the p53 family impinges on the activity of individual isoforms of the p53 family to suppress tumori genesis. Although p53, TAp63 and TAp73 can all induce apoptosis and cell cycle arrest through the transactivation of target genes, the ΔN isoforms of p63 and p73 can inhibit these activities 12 . These activities suggest that p53, TAp63 and TAp73 are tumour suppressors, whereas the ΔNp63 and ΔNp73 isoforms are oncogenic. Although there is still much left to understand about the complexes of p53 family members that are formed in different contexts and the downstream consequences for tumour suppression, it has become clear from mouse models that are deficient in Trp73 and Trp63, as well as from human tumour samples, that TAp73 and especially TAp63 are suppressors of metastasis 7, 9, 70, 71 . Moreover, recent studies have shown that both TAp73 (REFS 93, 94) and TAp63 (REFS 63, 95, 96) have important roles in metabolism. In the future, it will be interesting to understand how their functions in metabo lism impinge on their tumour suppressive activities.
How does p63 suppress metastasis? We know that p63 has crucial roles in epithelial biology. Functions for p63 have been found in epithelial differentiation 13 , adhesion 13, 14, 76 , stem cell maintenance 16 and proliferation 56, 75 . These functions in epithelial tissues have important consequences for the formation of a carcinoma and the cellular movements that are required for the multiple steps in metas tasis. It is important to be conscious of the TAp63 and ΔNp63 isoforms and their known activities in the skin. TAp63 maintains stem cells in the dermis in quiescence, but ΔNp63 is not expressed and has no role in these cells 16 . At the same time, ΔNp63 induces terminal differentiation of transiently amplifying cells in the epidermis, whereas TAp63 is dispensa ble for this function 30, 66 . This exemplifies how p63 isoforms have different functions in the same tissue, and there is a need to understand how these activities impinge on the cancer phenotypes that are observed in , making it important to understand how each p63 isoform may regulate processes in tumour progression, particularly in carcinomas, in which TAp63 and ΔNp63 expression is altered. Last, key p63 target genes that have important roles in epithelial adhesion and integrity, such as PERP, have been shown to be involved in the suppression of tumorigenesis and metastasis 98 . PERP is primarily transactivated by TAp63 isoforms, revealing further complex regulation of target genes by individual p63 isoforms. As PERP is a desmosomeassociated protein, this provides further evidence that understanding the roles of both TAp63 and ΔNp63 in cellular adhesion is key to unlocking the functions of p63 in metastasis.
Future work in the p63 field should aim to understand the molecular mechanisms of each individual isoform in regulating epithelial biology and the roles of these mechanisms in cancer development and metastasis. It will be crucial to identify the protein complexes that are formed in the family and the downstream consequences of such interactions in various tissues and con texts. Moreover, it will be crucial to integrate the pathways that are regulated by p63 with those that are regulated by p53 and p73. Such information can now be easily obtained by highthroughput sequencing using RNA-seq and ChIP-seq technologies coupled with antibodies for p53 family member isoforms in various cellular and biological contexts. A complete picture of the molecular biology that is regulated by the whole p53 family is emerging and is crucial for targeting this pathway therapeutically in human cancer.
